Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
|Articles|February 16, 2021
Supplements and Featured Publications
- Current and Emerging Trends in Chronic Myeloid Leukemia
- Volume 1
- Issue 1
Current and Future Trends in Chronic Myeloid Leukemia
Advertisement
This publication includes a summary of data on therapeutic agents for the current and future treatment landscape of chronic myeloid leukemia. Hematologic oncology experts provide key insights on approaching disease management, including a discussion on treatment options through later-line settings.
Articles in this issue
over 5 years ago
Dr. Cortes on the Future of Ponatinib in CML Treatmentover 5 years ago
Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CMLover 5 years ago
Dr. Sweet on Treatment Selection With TKIs in CMLAdvertisement
Related to this article
A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.
Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.
Nirav N. Shah, MD, MSHP, discusses bexobrutideg and what the BTK degrader could bring to chronic lymphocytic leukemia management.
OncLive spoke with expert investigators to gather insights on the role of AI in cancer care, including oncologic surgery and drug development.
Advertisement
Advertisement
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
The OncFive: Top Oncology Articles for the Week of 7/12
3
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
4
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
5